Management of malignant hyperthermia susceptible parturients

Anaesthesia and Intensive Care

Volumn 25, Issue 4, 1997, Pages 398-407

  Pollock, N A ^a   Langton, E E ^a  

^a PALMERSTON NORTH HOSPITAL   (New Zealand)

Author keywords

Anaesthesia, complications: malignant hyperthermia, parturients, stress, sympathomimetics, dantrolene, newborn

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT;

ADOLESCENT; ADULT; ARTICLE; CESAREAN SECTION; CLINICAL ARTICLE; DELIVERY; DISEASE PREDISPOSITION; FEMALE; GENERAL ANESTHESIA; HUMAN; LABOR; MALIGNANT HYPERTHERMIA; OBSTETRIC ANESTHESIA; PLACENTAL TRANSFER; PRACTICE GUIDELINE; STRESS;

EID: 0030879429     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x9702500413     Document Type: Article

References (69)

1. European MH group. A protocol for the investigation of malignant hyperthermia (MH) susceptibility. Br J Anaesth 1984; 56:1267-1269.
2. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80:771-779.
3. Lucy SJ. Anaesthesia for caesarean delivery of a malignant hyperthermia susceptible parturient. Can J Anaesth 1994; 41:1220-1226.
4. Douglas MJ, McMorland GH. The anaesthetic management of the malignant hyperthermia susceptible parturient. Can Anaesth Soc J 1986; 33:371-378.
5. Sorosky JI, Ingardia CJ, Botti JJ. Diagnosis and management of susceptibility to malignant hyperthermia in pregnancy. The American Journal of Perinatology 1989; 6:46-48.
6. Khalil SN, Williams JP, Bourke DL. Management of a malignant hyperthermia susceptible patient in labor with 2-chloroprocaine epidural anaesthesia. Anesth Analg 1983; 62:119-121.
7. Melzack R. The myth of painless childbirth. Pain 1984; 19: 321-337.
8. Lederman RP, Lederman E, Work BA, McCann DS. The relationship of maternal anxiety, plasma catecholamines, and plasma cortisol to progresss in labor. Am J Obstet Gynecol 1978; 132:495-500.
9. Lips FJ, Newland M, Dutton G. Malignant hyperthermia triggered by cyclopropane during cesarean section. Anesthesiology 1982; 56:144-146.
10. Cupryn JP, Kennedy A, Byrick RJ. Malignant hyperthermia in pregnancy. Am J Obstet Gynecol 1984; 150:327-328.
11. Liebenschultz F, Mai C, Pickerodt VWA. Increased carbon dioxide production in two patients with malignant hyperpyrexia and its control by dantrolene. Br J Anaesth 1979; 51:899-903.
12. Tettambel M. Malignant hyperthermia in an obstetric patient. J Am Osteopath Assoc 1980; 79:773-775.
13. Ward A, Chaffman MO, Sorkin EM. Dantrolene. Drugs 1986; 32:130-168.
14. Wadhwa RK. Obstetric anaesthesia for a patient with malignant hyperthermia susceptibility. Anesthesiology 1977; 46:63-64.
15. Klimanek J, Majewski W, Walencik K. A case of malignant hyperthermia during epidural analgesia. Anaesth Resus Intens Therap 1976; 4:143-145.
16. Katz JD, Krich LB. Acute febrile reaction complicating spinal anaesthesia in a survivor of malignant hyperthermia. Can Anaesth Soc J 1976; 23:285-289.
17. Larach MG. The North American Hyperthermia Registry, 1 June 1993, personal communication.
18. Yamashita M, Honda K, Iha H, Kondo S, Matsuki A, Oyama T. A case of acute hyperpyrexia with violent shivering immediately after operation under epidural anaesthesia supplemented by nitrous oxide. Can Anaesth Soc J 1982; 29:632-635.
19. Motegi Y, Shirai M, Arai M, Kato S, Kawana Y, Goto F. Malignant hyperthermia during epidural anesthesia. Journal of Clinical Anesthesia 1996; 8:157-160.
20. Wingard DW. Proc focus Malignant Hyperthermia Symposium Wausau, Wisconsin Sept 13 1974 Appleton-Century Crofts, New York 1977.
21. Fletcher R, Ranklev E, Olsson A, Leander S. Malignant hyperthermia syndrome is an anxious patient. Br J Anaesth 1981; 53:993-995.
22. Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in external heat stroke and malignant hyperthermia. Lancet 1991; 338:1491-1492.
23. Hall GM, Lucke JN. Of man and pigs: is malignant hyperthermia a stress-related disorder. Stress Medicine 1985; 1:47-53.
24. Gronert GA. Malignant hyperthermia. Anesthesiology 1980; 53:395-423.
25. Bonica JJ, McDonald JS. Principles and Practice of Obstetric Analgesia and Anaesthesia (2nd ed.), Williams & Wilkins, Baltimore 1995, 62-66.
26. Britt BA. The clinical aspects of malignant hyperthermia. In: Nalda Felipe MA, Gottman S, Khambatta HJ, eds. Malignant hyperthermia: current concepts. Normed Verlag, Bad Homburg 1989; 91-107.
27. Hackl W, Mauritz W, Schemper M, Winkler M, Sporn P, Steinbereithner K. Prediction of malignant hyperthermia susceptibility: statistical evaluation of clinical signs. Br J Anaesth 1990; 64:425-429.
28. Larach MG, Rosenberg H, Larach DR, Broennie AM. Prediction of malignant hyperthermia susceptibility by clinical signs. Anesthesiology 1987; 66:547-550.
29. Fusi L, Steer PJ, Maresh MJA, Beard RW. Maternal pyrexia associated with the use of epidural analgesia in labour. Lancet 1989;i:1250-1252.
30. Pearson JF, Davies P. The effect of continuous lumbar epidural analgesia on maternal acid-base balance and arterial lactate concentration during the second stage of labour. J Obstet Gynaecol Br Commonw 1973; 80:225-229.
31. Weissberg N, Shemesh O, Schwartz G, Brisk R, Eylath U, Abraham AS. The rise of serum creatine levels during labor. Archives of Gynecology and Obstetrics 1991; 249:33-37.
32. Shnider SM, Abboud TK, Artal R, Henriksen EH, Stefani SJ, Levinson G. Maternal catecholamines decrease during labor after lumbar epidural anesthesia. Am J Obstet Gynecol 1983; 147:13-15.
33. Gin T, Gregory MA, Oh TE. The haemodynamic effects of propofol and thiopentone for induction of caesarean section. Anaesth Intens Care 1990; 18:175-179.
34. Abboud TK, Zhu J, Richardson M, Peres Da Silva E, Donovan M. Intravenous propofol vs thiamylal-isoflurane for caesarean section, comparative maternal and neonatal effects. Acta Anaesthesiol Scand 1995; 39:205-209.
35. McKenzie AJ, Couchman KG, Pollock N. Propofol is a "safe" anaesthetic agent in malignant hyperthermia susceptible patients. Anaesth Intensive Care 1992; 20:165-168.
36. Abouleish E, Abboud T, Lechevalier T, Zhu J, Chalian A, Alford K. Rocuronium (Org 9426) for caesarean section. Br J Anaesth 1994; 73:336-341.
37. Haggendal J, Jonsson L, Carlsten J. The role of sympathetic activity in initiating malignant hyperthermia. Acta Anaesthesiol Scand 1990; 34:677-682.
38. Hall GM, Lucke JN, Lister D. Porcine malignant hyperthermia. V: Fatal hyperthermia in the Pietrain pig, associated with the infusion of alpha-adrenergic agonists. Br J Anaesth 1977; 49:855-862.
39. Gronert GA, Milde JH, Theye RA. Role of sympathetic activity in porcine malignant hyperthermia. Anesthesiology 1977; 47:411-415.
40. Gronert GA, Milde JH, Taylor SR. Porcine muscle responses to carbachol and alpha and beta adrenoceptor agonists, halothane or hyperthermia. J Physiol (Lond) 1980; 307: 319-333.
41. Gronert GA, Ahern CP, Milde JH, White RD. Effect of carbon dioxide, calcium, digoxin, and potassium on cardiac and skeletal muscle metabolism in malignant hyperthermia susceptible swine. Anesthesiology 1986; 64:24-28.
42. Marconi RM, Wedel DJ, Hofer RE. Norepineprine does not potentiate porcine malignant hyperthermia. Anesth Analg 1996; 82:790-795.
43. Urwyler A, Censier K, Seeberger MD, Rothenbuhler JM, Kaufman MA, Drewe J. In vitro effect of ephedrine, adrenaline, noradrenaline and isoprenaline on halothane-induced contractures in skeletal muscle from patients potentially susceptible to malignant hyperthermia. Br J Anaesth 1993; 70:76-79.
44. Bendixen D, Ording H. Influences of salbutamol on the in vitro muscle response to caffeine and halothane in malignant hyperthermia. Acta Anaesthesiol Scand 1990; 34:658-661.
45. MHAUS Professional Advisory Council adopts new policy statement on local anaesthetics. Communicator 1985; 3:1.
46. Tatsukawa H, Okuda J, Kondoh M, et al. Malignant hyperthermia caused by intravenous lidocaine for ventricular arrhythmia. Intern Med 1992; 31:1069-1071.
47. Sim ATR, White MD, Denborough MA. The effect of oxytocin on porcine susceptible malignant hyperpyrexia susceptible skeletal muscle. Clinical and Experimental Pharmacology and Physiology 1987; 14:605-610.
48. Flewellen EH, Nelson TE. In vivo and in vitro responses to magnesium sulphate in porcine malignant hyperthermia. Can Anaesth Soc J 1980; 27:363-369.
49. Lerman J, Relton JES. Anaesthesia for malignant hyperthermia susceptible patients. In: Britt BA, ed. Malignant Hyperthermia. Martinus Nijhoff Publishing Boston 1987; 369-392.
50. Harrison GG. The prophylaxis of malignant hyperthermia by oral dantrolene sodium in swine. Br J Anaesth 1977; 49:315-317.
51. Free CW, Jaimon MPC. Pre-anaesthetic administration of dantrolene sodium to a patient at risk from malignant hyperthermia: case report. New Zealand Medical Journal 1978; 88:493.
52. Flewellen EH, Nelson TE. Dantrolene dose response in malignant hyperthermia-susceptible (MHS) swine: method to obtain prophylaxis and therapeusis. Anesthesiology 1980; 52:203-208.
53. Morison DH. Placental transfer of dantrolene. Anesthesiology 1983; 59:265.
54. Glassenberg R, Cohen H. Intravenous dantrolene in a pregnant maligant hyperthermia susceptible (MHS) patient. Anesthesiology 61: 1984:A404.
55. Shine J, Gare D, Andrews J, Britt BA. Dantrolene in pregnancy: lack of adverse effects on the fetus and newborn infant. Am J Obstet Gynecol 1988; 159:831-834.
56. Hackl W, Mauritz W, Winkler M, Sporn P, Steinbereithner K. Anaesthesia in malignant hyperthermia susceptible patients without dantrolene prophylaxis: a report of 30 cases. Acta Anaesthesiol Scand 1990; 34:534-537.
57. Cunliffe M, Lerman J, Britt BA. Is prophylactic dantrolene indicated for MHS patients undergoing elective surgery. Anesth Analg 1987; 66:S35.
58. Ording H, Hendengran AM, Skovgaard LT. Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia. Acta Anaesthesiol Scand 1991; 35:711-716.
59. Wedel DJ, Quinlan JG, Iaizzo PA. Clinical effects of intravenously administered dantrolene. Mayo Clin Proc 1995; 70:241-246.
60. Gallant EM, Foldes FF, Rempel WE, Gronert GA. Verapamil is not a therapeutic adjunct to dantrolene in porcine malignant hyperthermia. Anesth Analg 1985; 64:601-606.
61. Rubin AS, Zablocki AD. Hyperkalaemia, verapamil and dantrolene. Anesthesiology 1987; 66:246-249.
62. Rosenblatt R, Tallman RD, Weaver J, Wang Y. Dantrolene potentiates the toxicity of bupivacaine. Anesthesiology 1984; 61:A209.
63. Weingarten AE, Korsh JI, Neuman GC, Stern SB. Postpartum uterine atony after intravenous dantrolene. Anesth Analg 1987; 66:269-270.
64. Johnson C. Pregnancy and malignant hyperthermia. J Clin Anesth 1992; 4:173.
65. Pollock N, Hodges M, Sendall J. Prolonged malignant hyperthermia in the absence of triggering agents. Anaesth Intens Care 1992; 20:520-523.
66. Sewall K, Flowerdew RMM, Bromberger P. Severe muscular rigidity at birth: malignant hyperthermia syndrome? Can Anaesth Soc J 1980; 27:279-282.
67. Kvisselgaard N, Moya F. Investigation of placental thresholds to succinylcholine. Anesthesiology 1961; 22:7-10.
68. Dabrovka J, Crul JF, Van der Kleijn E. Placental transfer of 14C labelled succinylcholine in near-term Macaca Mulatta monkeys. Br J Anaesth 1973; 45:1087-1095.
69. Baraka A, Haroun S, Bassili M, Abu-Haider G. Response of the newborn to succinylcholine injection in homozygotic atypical mothers. Anesthesiology 1975; 43:115-116.